The invention relates to a microchannel device for preparation of sperm, the device comprising: an inlet; an extraction zone; and a channel fluidly connecting the inlet to the extraction zone; wherein the channel comprises a plurality of orienting features operable to bias a direction of sperm cell movement within the channel towards a preferred direction; and wherein the channel has a length of approximately 1 centimetre or greater. Further, the invention relates to a method of sperm preparation using the microchannel device.
A formulation comprises polysaccharide aggregates suspended in an aqueous medium and a salt. The only polysaccharides present in the formulation are the polysaccharides which form the aggregates. The formulation may find use in the treatment or prevention of fibrosis or scarring. The formulation can be prepared by dissolving a polysaccharide in an aqueous medium at a temperature of at least 50 °C to form a solution, cooling the solution, and adding a salt to the cooled solution while stirring.
The present disclosure relates to the use of ATM inhibitors, such as AZ1390 and related compounds, in the treatment of various neurological conditions, by protecting against or treating neuronal damage or neuronal degeneration, including traumatic injury, such as spinal cord injury (SCI).
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A method of providing a prognosis to a subject, the method comprising: i. providing a biological sample obtained from the subject; ii. determining the level of a panel of biomarkers comprising or consisting of SPATA 19, SPACA3, TSPY3, TCEA2, TSGA10, and LUZP4 in the sample; iii. comparing the level of the panel of biomarkers in the sample with a reference level of the same panel of biomarkers; iv. using the results from (iii) to provide a prognosis to the subject. More particularly, a method of providing a prognosis to a subject with cancer.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
5.
NOVEL PHOSPHOANTIGEN PRODRUG COMPOUND AND USE THEREOF
UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (Royaume‑Uni)
UNIVERSITY OF BIRMINGHAM (Royaume‑Uni)
Inventeur(s)
Mehellou, Youcef
Willcox, Benjamin
Abrégé
The invention relates to a novel phosphoantigen (PAg) prodrug compound which provides for a potent activation of therapeutically active γδ T cells. The PAg prodrug compound of the in- vention can be used for the preparation of therapeutically active γδ T cells as well as in the immunotherapy of different diseases, and in particular different types of cancer. The invention further relates to a method for expanding γδ T-cells ex vivo which makes use of the PAg pro-drug compound of the invention. Also provided are γδ T-cells which have been expanded with the PAg prodrug compound of the invention and pharmaceutical compositions comprising such expanded cells and/or the PAg prodrug compound of the invention.
This detection system comprises: a detection signal acquisition unit 306 that acquires, as a detection signal, a signal from an object being detected; and a noise-removed signal acquisition unit 307 that inputs the detection signal to a noise removal model 304 trained using noise signals obtained when no object is detected, and acquires at least one noise-removed signal, from which noise has been removed.
The invention provides an assay useful in predicting risk of capecitabine-induced toxicity in a subject. The subject may be screened for the presence of at least one polymorphism of the invention. Suitable polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing capecitabine-induced toxicity; a negative result may indicate a decreased risk of developing capecitabine-induced toxicity.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A method of forming an implant for the repair of defects in bone. the method comprises the steps of: electrospinning bioactive glass fibres: compressing the electrospun bioactive glass fibres to form a compressed body: heating the compressed body to bond the fibres to form a shaped body: heat treating the shaped body to form a heat-treated shaped body. There is also disclosed an implant for use in repairing critical or sub critical bone defects.
A method of isolating or suppressing forced oscillations in a power grid by utilising a wind turbine system comprising a wind turbine for capturing wind power, a generator driven by the wind turbine, and a power converter configured to control the rotational speed of the generator for controlling a supply of active power to the power grid. The power converter is further configured to supply reactive power to the power grid independently from the supply of active power. The method comprising the steps of: obtaining measurements of a forced oscillation occurring within the power grid; controlling the converter to supply active and reactive corrective oscillating power to the power grid in response to the measured forced oscillation such that the corrective oscillating power suppresses the forced oscillations.
H02J 3/24 - Dispositions pour empêcher ou réduire les oscillations de puissance dans les réseaux
F03D 7/02 - Commande des mécanismes moteurs à vent les mécanismes moteurs à vent ayant l'axe de rotation sensiblement parallèle au flux d'air pénétrant dans le rotor
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
A mobile platform (C) comprising an energy storage system, the system comprising a sorbent and sorbate pair, the system further comprising a first chamber (11), a second chamber (13), a fluid flow conduit (12) fluidly connecting the first chamber (11) and the second chamber (13), and a microwave generator (21), wherein the microwave generator (21) is operable in use to desorb the sorbate from the sorbent in the first chamber (11) to release thermal energy from the second chamber (13), and wherein the second chamber (13) is thermally connectable to a source of fluid to condense the sorbate and thereby heat the fluid.
F28D 20/00 - Appareils ou ensembles fonctionnels d'accumulation de chaleur en généralAppareils échangeurs de chaleur de régénération non couverts par les groupes ou
An apparatus for driving atoms of an atom cloud into a targeted quantum state is provided, the apparatus comprising: an atom source for releasing a cloud of atoms to be driven into a targeted quantum state; a laser system configured to generate a laser beam to be directed onto the atom cloud in use, the laser beam having a frequency corresponding to a resonant frequency of an atomic transition for exciting the atoms into the targeted quantum state; a modulator configured to, in use, modulate the frequency of the laser beam responsive to an input signal; a waveform generator coupled to the modulator and configured to, in use, generate an input signal for the modulator, wherein the input signal is arranged to cause the modulator to modulate the laser light to generate a comb of frequencies around the resonant frequency of the atomic transition, the frequency comb including a plurality of peaks, each peak being separated by a frequency spacing, δω, that is determined based on a Rabi frequency, Ω, of the atomic transition to drive atoms of the atom cloud into a targeted quantum state.
A method of diagnosis utilising a lab-on-a-chip (LoC). The LoC comprising an inlet well (61) and a succession of sampling wells (11,21,31,41,51) arranged in fluid communication via capillary channels (14,24,34,44,54) and a filter (15,25,34,45,55) provided between each of the inlet well (61) and a first sampling well (51) and between adjacent sampling wells (11,21,31,41) with each successive filter having a smaller pore size. The method comprising: applying a biofluid sample comprising extracellular vesicles to the inlet well (61); the biofluid sample being drawn along the succession of sampling wells (11,21,31,41,51); the extracellular vesicles being separated by the filters (15,25,35,45) into a plurality of subclasses determined by their size, each subclass being isolated in a separate sampling well (11,21,31,41,51) and collecting identifying data on the extracellular vesicles in each sampling well (11,21,31,41,51).
A lab-on-a-chip (LoC) (1) comprising a plurality of sampling wells (51, 41) and a nano-porous filter (45). A first sampling well (51) in fluid communication with a second sampling well (41) via a flow path. The nano-porous filter (45) being provided in the first sampling well (51).
The present disclosure relates to methods and products for use in detecting target RNA sequences in a sample, based on a process which nicks the DNA strand of a DNA/RNA duplex and amplifies a product thereof
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
15.
TREATMENT OF OBESITY-ASSOCIATED INFLAMMATORY CONDITIONS
The present invention concerns a peptide comprising the amino acid sequence SVTEQGAELSNEER, or variants thereof for use in the prophylaxis or treatment of obesity-associated inflammatory conditions such as obesity-induced chronic low-grade systemic inflammation and pancreatic beta-cell damage. Methods of treatment or prophylaxis of obesity-associated inflammatory conditions comprise administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER, or variants thereof, to a patient in need thereof.
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
16.
PREPARATION OF COLD ATOM CLOUDS FOR MEASURING GRAVITY GRADIENT
An apparatus for generating vertically separated atom clouds. The apparatus comprises an optical system comprising an arrangement of lenses and optics. The optical system is configured to trap and cool atoms to form a cold atom cloud; select the hyperfine level of the atoms; trap atoms of the cold atom cloud in a standing wave optical lattice; and vertically split the cold atom cloud into a high cold atom cloud and a low cold atom cloud. The splitting comprises splitting the cold atom cloud into two clouds by launching atoms of the cold atom cloud in opposite directions to form a high cold atom cloud and a low cold atom cloud, and catching the low cold atom cloud up to reach the same velocity as the high cold atom cloud.
A single arm laser system comprising a first in-phase quadrature modulator, IQM. The first IQM is configured to receive a single frequency fibred laser beam from a frequency locked laser seed, generate a first single side-band frequency based on a carrier frequency of the single frequency fibred laser beam and suppress the carrier frequency, and output a first fibre laser beam having a single side-band suppressed carrier frequency. The single arm laser system also comprises a second IQM in line with the first IQM. The second IQM is configured to receive the first fibre laser beam from the first IQM, generate a second single side-band frequency based on the first single side-band frequency and maintain the first single side-band frequency as the carrier frequency, and output a second fibre laser beam having the first and second single side band frequencies.
H01S 3/107 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation par commande de dispositifs placés dans la cavité utilisant des dispositifs électro-optiques, p. ex. produisant un effet Pockels ou Kerr
G01V 7/04 - Moyens électriques, photo-électriques ou magnétiques d'indication ou d'enregistrement
H01S 3/106 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation par commande de dispositifs placés dans la cavité
H01S 3/109 - Multiplication de la fréquence, p. ex. génération d'harmoniques
The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.
The invention relates to a peptide conjugate comprising a peptide covalently linked to a label, wherein the peptide comprises an amino acid sequence of a protein ligand that binds at least one class B1 G protein-coupled receptor, wherein the peptide is covalently linked to the label. The protein ligand is preferably an agonist, antagonist and/or co-agonist of at least one class B1 G protein-coupled receptor, preferably from the Glucagon-like subfamily. The agonist, antagonist and/or co-agonist is preferably selected from tirzepatide, LY3437943 or GIF. The invention further relates to kits comprising the peptide conjugate according to the invention or means for assembling the conjugate, as well as methods for using the peptide conjugate according to the invention.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention relates generally to materials and methods of inhibiting Long Terminal Repeat Transposable Elements (LTR-TEs) during propagation of a plant by use of a reverse transcriptase inhibitor. Methods include propagation by plant tissue culture, comprising culturing an initial plant tissue in a culture medium comprising a reverse transcriptase inhibitor to obtain the cultured plant tissue, whereby inhibiting LTR-TEs leads to reduction in somaclonal variation in cultured plant tissue. Also provided are related media adapted for such culture, and plants and tissues which have reduced genetic variation as a result of the method.
Provided is a method of activating T cells, the method including contacting the T cells with a plurality of magnetic nanoparticles (MNPs), wherein each MNP is functionalized with a T cell receptor (TCR) binding moiety, and exposing the T cells to a magnetic field. The method finds utility in the treatment of cancer and autoimmune disease.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A phase shifter (400) comprises a substrate integrated waveguide, at least one controllable element (420), at least one fluid channel, and a liquid disposed in the at least one fluid channel. The substrate integrated waveguide comprises a substrate, a first conductor layer on a first side of the substrate, a second conductor layer on a second side of the substrate, and a plurality of edge vias (403) defining a conducting path between the first conductor layer and the second conductor layer. The first conductor layer, second conductor layer and the plurality of edge vias (403) define a waveguide core for propagation of radio frequency signals. Each controllable element (420) comprises a pad, a via and a slot, wherein the pad and slot are defined in one of the first conductor layer or the second conductor layer, the slot isolating the pad, and the via defines a conducting path between the pad and the other of the first conductor layer and the second conductor layer. The at least one fluid channel is disposed on the first conductor layer and/or the second conductor layer and is configured to allow fluid communication with each slot. The at least one controllable element (420) is configured to be controlled by movement of the liquid within the at least one fluid channel, thereby causing a phase shift in the radio frequency signals as a result of bridging of at least one slot by the liquid.
OXFORD UNIVERSITY INNOVATION LIMITED (Royaume‑Uni)
THE UNIVERSITY OF BIRMINGHAM (Royaume‑Uni)
Inventeur(s)
Palles, Claire
Kerr, David
Kerr, Rachel
Abrégé
The invention relates to an assay. More specifically, the invention relates to an assay for predicting cardiovascular toxicity of a chemotherapeutic agent.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The present invention provides a method of stratifying test subjects with Polycystic Ovary Syndrome (PCOS) into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising: (a) providing a test sample from a test subject with PCOS; (b) determining the concentration/level in the test sample of at least one ovarian androgen steroid and/or a derivative thereof, and at least one adrenal steroid and/or derivative thereof; and (c) using the results from (b) to predict if the subject will respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, therapeutic treatment with an AKR1C3 inhibitor, or therapeutic treatment with a 5alpha-reductase inhibitor.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
25.
MODULATORS OF CD1 PROTEIN BINDING TO T CELL RECEPTORS
C07H 15/10 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide contenant des liaisons non saturées carbone-carbone
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
An implantable device (101) for drug delivery to a patient, the device comprising a housing (103) defining an enclosed space (106), a catheter port (102) that provides fluid access to the enclosed space, a permeable release zone (105) that permits drug release from the enclosed space, and an attachment portion (104) for attaching the housing at a location, such that, in use, the implantable device can be placed within the body of the patient and attached, using the attachment portion, at a location such that the release zone is adjacent to a treatment site, and whereby a drug composition in fluid form can be provided to the enclosed space via a catheter (108) and the catheter port, and the drug can be released to the treatment site via the permeable release zone.
A system (100) for metal production, the system comprising: a reducing furnace (110) configured to receive metal ore (101) and process gas (102) and to output hot metal (115) and reducing furnace top gas (111); and a first thermochemical reactor (130) configured to, in a first mode, receive at least a portion (163) of the reducing furnace top gas (111), and to produce carbon monoxide from carbon dioxide in the portion (163) of the blast reducing furnace top gas (111) by oxidation of a thermochemical compound and to return at least a portion of the produced carbon monoxide (151) to the reducing furnace (110).
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A system for improving cognitive function is disclosed. The system comprises a non-invasive brain stimulation device (150); a human computer interface; and a computer (101) configured to control the non-invasive brain stimulation device (150) and the human computer interface. The computer (101) controls the brain stimulation device (150) and the human computer interface to assess a subject's baseline cognitive function by interaction with the subject using the human computer interface. If the subject's baseline cognitive function is impaired, the computer (101) uses the human computer interface to provide the subject with a strategy for improving performance in a cognitive function test and stimulates the subjects brain with the non-invasive brain stimulation device (150) while training the subjects cognitive function.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
A61B 5/383 - Stimuli somatosensoriels, p. ex. stimulation électrique
30.
METHOD OF MANUFACTURING A COMPONENT FOR USE IN HIGH TEMPERATURE ENVIRONMENT, FIRST SUBSTRATE
A method of manufacturing a component (5) for use in a high temperature environment, the method comprises the sequential steps of: i) providing a first substrate (10) comprising a body having a surface, ii) securing a bonding material (13) to the surface of the first substrate (10), iii) removing at least some of the substrate (10) and bonding material (13) to provide a formation (14z) extending into the body (10), and iv) securing a second substrate (11) to the first substate using at least some of the bonding material.
B23K 1/20 - Traitement préalable des pièces ou des surfaces destinées à être brasées, p. ex. en vue d'un revêtement galvanique
B23K 20/02 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p. ex. revêtement ou placage au moyen d'une presse
B23K 20/16 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p. ex. revêtement ou placage en interposant un matériau particulier facilitant l'assemblage des pièces, p. ex. un matériau absorbant ou produisant des gaz
B23K 20/233 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p. ex. revêtement ou placage tenant compte des propriétés des matériaux à souder sans couche ferreuse
F01D 5/00 - AubesOrganes de support des aubesDispositifs de chauffage, de protection contre l'échauffement, de refroidissement, ou dispositifs contre les vibrations, portés par les aubes ou les organes de support
B23K 101/00 - Objets fabriqués par brasage, soudage ou découpage
B23K 103/18 - Matériaux comportant des matières différentes
The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1-54, which may be encoded by SEQ ID NOS: 55-110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
UNIVERSITY HOSPITAL BIRMINGHAM NHS FOUNDATION TRUST (Royaume‑Uni)
Inventeur(s)
Nieto, Thomas George
Stockton, Joanne Dawn
Beggs, Andrew David
Abrégé
The invention relates to a set of oligonucleotides, and a kit comprising a set of oligonucleotides where the oligonucleotides are for use in determining the HLA genotype of a DNA sample. The invention also relates to a method of determining the HLA genotype of a DNA sample. The method may be used to identify a suitable donor and/or recipient of a transplant, for paternity testing, to identify the HLA type for determination of epitope binding capability in neo-antigen prediction, or for diagnosing an immune disorder such as ankylosing spondylitis. The method preferably uses long-range PCR and long read sequencing preferably using a Type R10 nanopore.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
A photocurable resin composition comprising a crosslinker (104), the crosslinker (104) comprising plural cyclic disulphide groups and wherein the concentration of disulphide bonds in the resin composition is at least 10 wt.%.
The present invention relates to the identification of novel therapeutic targets and their use in the mitigation of inflammatory pathologies. In particular, the present invention concerns the field of anti-interleukin-17A antibodies, pharmaceutical compositions comprising said antibodies and medical uses of the same. Further aspects of the invention relate to a polynucleotide encoding the anti-interleukin-17A, vectors comprising the polynucleotide and host cells incorporating said vectors. In a further aspect the invention describes a peptide for the identification of anti- interleukin-17 compounds.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (France)
UNIVERSITÉ PARIS CITÉ (France)
UNIVERSITY OF DUNDEE (Royaume‑Uni)
TECHNICAL UNIVERSITY OF DRESDEN (Allemagne)
LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (Allemagne)
UNIVERSITY OF BIRMINGHAM (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (Royaume‑Uni)
Inventeur(s)
Zennaro, Maria-Christina
Jefferson, Emily
Reel, Parminder Singh
Reel, Smarti
Eisenhofer, Graeme
Reincke, Martin
Beuschlein, Félix
Taylor, Angela Elizabeth
Arlt, Wiebke
Lang, Katharina
Prete, Alessandro
Mackenzie, Scott
Davies, Eleanor
Abrégé
The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen- specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.
The present disclosure is based in part on studies that identify upregulation of markers in response to stimulation by an antigen (also referred to as activation induced markers) to detect antigen-specific immune cells, and uses thereof. The disclosure provides methods for identifying antigen-specific T cells produced in response to stimulation by an antigen.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
38.
A METHOD AND A SYSTEM FOR DETERMINING A CONCENTRATION OF MAGNETIC NANOPARTICLES
The present teaching relates to peptides that are capable of regulating the trafficking of leukocytes. This has applications in the treatment and/or prophylaxis of conditions associated with leukocyte migration, including inflammatory diseases and/or musculoskeletal (MSK) loss and/or damage.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The invention relates to a genetic probe, wherein the genetic probe comprises: an oligonucleotide, or an oligonucleotide analogue, with a Raman-active moiety incorporated therein, wherein the Raman-active moiety is incorporated into a base of the oligonucleotide or oligonucleotide thereof; and associated methods, uses, kits and compositions for determining a single point variant nucleotide in a target nucleic acid.
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The present disclosure describes, in part, a polymer, for example a thermoplastic polyurethane elastomer, comprising one or more subunits comprising (i) at least one dianhydrohexitole moiety (ii) at least one urethane moiety and (ill) a thiol moiety having two or more sulphur atoms. The thermoplastic polyurethane elastomers may be biodegradable and possess excellent thermoplastic properties, including outstanding toughness, resulting from its semi-crystallinity and low glass transition temperature, that surpasses many leading plastics such as nylon 6 and high-density polyethylene (HOPE) and methods of making same.
A method (2800) of selectively leaching one or more manganese-containing phases from a mixed-phase battery electrode material comprises treating (2802) the mixed-phase battery electrode material with a solution of an acid, the acid acting as both a leaching agent and a reducing agent, so as to form a manganese-containing leachate whilst leaving at least one phase of the battery electrode material unleached, wherein the acid has a pKa greater than or equal to −2. Either or both of the leachate and the remaining electrode material may then be regenerated (2806, 2808).
C22B 7/00 - Mise en œuvre de matériaux autres que des minerais, p. ex. des rognures, pour produire des métaux non ferreux ou leurs composés
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
The present invention relates to a system and a device for use in the diagnosis of an oral disease. Methods, kits and compositions for use in the diagnosis of oral disease are also provided. More particularly, the invention relates to a system comprising a probe which is configured to collect a fluid sample from the oral cavity of a subject, and a detector which is configured to detect in the fluid sample the presence and/or concentration of an analyte which is indicative of the oral disease.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A desalination system and a method for operating the desalination system. An example desalination system includes a partitioned container, a membrane container housing a cross-flow semipermeable membrane, a feed pump for supplying saline water, a recirculation pump, a main valve, a bypass valve and a purge valve. The system operates in a first pressurisation stage where saline water is provided by the feed pump while the bypass valve is open, followed by a second pressurisation stage where an upstream compartment of the container is filled and a recharge stage where the main valve is closed and concentrated saline water is purged via the purge valve. An inlet valve may be provided, which is closed in the first pressurisation stage and open in the second pressurisation stage and recharge stage.
The present disclosure relates to the treatment of eye conditions, by inhibiting Chk2 kinase. Particular ocular conditions may be associated with neuronal damage/dysfunction in the eye, or neurons in communication with the eye, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption inblood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.
The present invention relates to a sprayable antiviral formulation comprising an antiviral agent and a carrier polymer, wherein the antiviral agent comprises a sulphated polysaccharide and the carrier polymer comprises a non-sulphated polysaccharide. In particular, the present invention relates to a sprayable antiviral formulation which can be used as a nasal spray or as a multi-surface spray.
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
The present disclosure relates to the treatment of neurological conditions, by inhibiting Chk2 kinase. Particular neurological conditions may be associated with neuronal damage/dysfunction or neurological degeneration, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption in blood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
48.
SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER
The present invention provides rotaxanes comprising a macrocycle surrounding an ion comprising a blocking group capable of trapping the macrocycle. Also provided are methods of making such rotaxanes and a method of removing the blocking group from the rotaxane, thereby allowing the ion to escape the macrocycle. The ions have been found to have anticancer, antibacterial and/or antiviral properties. Accordingly, the rotaxanes of the invention may be useful in the treatment of cancer, bacterial and/or viral diseases.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A method for determining geometry of a face mask comprising a main body and a seal configured to engage a nasal region, cheeks and a chin of a user. The method comprises collecting (402) facial data of the user comprising a point cloud comprising a plurality of points on a skin surface in a nasal region, eye region and chin region of the user; determining (406), based on the facial data, in at least one of the eye region and the chin region of the user, an estimated face size of the user; determining (408), based on the facial data comprising the plurality of points in the nasal region, a best-fit Gaussian curve to a profile of a nose of the user; and using the estimated face size of the user and the determined Gaussian curve to select (410) parameters for a profile geometry of the face mask.
Provided is a method of diagnosing and/or monitoring traumatic brain injury (TBI) in a subject. The method comprises determining a level of at least one miRNA in a fluid sample from the subject. The miRNA may be selected from miR-425-5p, miR-502, miR-21 and miR-335. The method may involve determining whether a subject is suffering from mild-TBI or moderate-to-severe TI. Also provided is a sensor element, a detection system, composition and a kit for diagnosing and/or monitoring TBI, and a method of determining an appropriate treatment for a subject with a suspected TBI.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
There is disclosed a reconfigurable metasurface device comprising a planar dielectric substrate and a two dimensional array of substantially planar conductive elements formed on or in the dielectric substrate. The two dimensional array of substantially planar conductive elements consists of alternating rows and columns of first and second substantially planar conductive elements, the first conductive elements each having a first shape with a first width and height, and the second conductive elements each having a second shape with a second width and height. The alternating rows and columns are offset with respect to each other such that centroids of the first shapes are disposed centrally between centroids of the second shapes of each adjacent row, and centroids of the first shapes of one column are disposed centrally between centroids of the second shapes in each adjacent column. The device further comprises a conductive ground plane disposed adjacent and substantially parallel to the two dimensional array of conductive elements so as to define an air gap between the two dimensional array of conductive elements and the conductive ground plane, and a micro-actuator configured to adjust or vary a thickness of the air gap.
H01Q 15/00 - Dispositifs pour la réflexion, la réfraction, la diffraction ou la polarisation des ondes rayonnées par une antenne, p. ex. dispositifs quasi optiques
Articles comprising a porous surface and having on said porous surface a coating comprising nanocellulose, methods of applying a coating comprising nanocellulose to a porous substrate, compositions comprising nanocellulose, and the use of such compositions in methods of improving filtration efficiency and preparing an antimicrobial surface and/or antiviral surface coating.
A01N 43/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à six chaînons avec l'oxygène comme hétéro-atome du cycle
A01N 25/34 - Formes façonnées, p. ex. feuilles, non prévues dans l'un quelconque des autres sous-groupes du présent groupe principal
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
Provided is a method of diagnosing and/or monitoring mild traumatic brain injury (mTBI) or concussion in a subject. The method comprises determining a level of at least one miRNA in a saliva sample from the subject. Also provided is a sensor element, a detection system, composition and a kit for diagnosing and/or monitoring TBI, and a method of determining an appropriate treatment for a subject with suspected mTBI or concussion.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
There is disclosed a leaky-wave antenna device comprising a first metasurface comprising a first dielectric substrate having a first array of conductive elements and a second metasurface comprising a second dielectric substrate having a second array of conductive elements. The antenna device further comprises a conductive ground plane, a micro-actuator, and a feed comprising a pair of switchable dipoles. The first and second metasurfaces and the conductive ground plane are in a stacked arrangement and substantially parallel to one another, with the first metasurface located between the second metasurface and the conductive ground plane. A spacing between the conductive ground plane and the first metasurface is adjustable by operation of the micro-actuator. The feed is disposed between the first and second metasurfaces at a location corresponding to a centre of the first and second arrays. The leaky-wave antenna device may be operated to steer a beam over a wide range by selective energising of the pair of dipoles and by adjusting the spacing between the conductive ground plane and the first metasurface.
H01Q 3/16 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne utilisant un mouvement mécanique relatif entre des éléments actifs primaires et des dispositifs secondaires des antennes ou systèmes d'antennes pour faire varier la position relative d'un élément primaire actif vis-à-vis d'un dispositif réfléchissant
H01Q 13/28 - Antennes constituées par un guide non résonnant à ondes de fuite ou une ligne de transmissionStructures équivalentes produisant un rayonnement le long du trajet de l'onde guidée comportant des éléments présentant des discontinuités électriques et espacées dans la direction de la propagation de l'onde, p. ex. élément diélectrique ou élément conducteur formant diélectrique artificiel
H01Q 15/00 - Dispositifs pour la réflexion, la réfraction, la diffraction ou la polarisation des ondes rayonnées par une antenne, p. ex. dispositifs quasi optiques
55.
Frequency control of orthogonal polarisation modes in an optical cavity
The application discloses an atom interferometer comprising an optical cavity and method of operation thereof. The atom interferometer includes a vacuum chamber, an optical cavity, a source for providing a cloud of atoms in the optical cavity in use, and one or more light sources. The one or more light sources are for generating, in the cavity, in use a first light beam having a first polarisation and at a first frequency for a two-photon interaction in the atoms; and a counterpropagating second light beam having a second polarisation orthogonal to the first polarisation and at a second frequency for the two-photon interaction in the atoms. The atom interferometer also includes an electro-optic element arranged in the cavity to be operable to simultaneously change; the resonant frequency of the cavity for light in the first polarisation to track changes in the frequency of the first light beam to compensate for the doppler shift of the falling atoms in use; and the resonant frequency of the cavity for light in the second polarisation to track changes in frequency of the counterpropagating second light beam to compensate for the doppler shift of the falling atoms in use.
G01B 9/02002 - Interféromètres caractérisés par la commande ou la génération des propriétés intrinsèques du rayonnement utilisant plusieurs fréquences
G01B 9/02001 - Interféromètres caractérisés par la commande ou la génération des propriétés intrinsèques du rayonnement
G02F 1/03 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des céramiques ou des cristaux électro-optiques, p. ex. produisant un effet Pockels ou un effet Kerr
G02F 1/21 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence
G01C 19/62 - Gyromètres à résonance magnétique nucléaire ou électronique avec pompage optique
G01V 7/00 - Mesure de champs ou d'ondes de gravitationProspection ou détection gravimétrique
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
The invention relates to a method of generating bone marrow organoids from pluripotent stem cells wherein said method comprises: a) driving induced pluripotent stem cells (iPSCs) to form mesodermal aggregates; b) inducing vascular and hematopoietic commitment of the mesodermal aggregates by further culturing the mesodermal aggregates in medium, supplemented with recombinant BMP4, FGF2, VEGFA and SCF; c) embedding the mesodermal aggregates in a hydrogel, and incubating the hydrogel in a sprouting medium comprising: a media suitable for stem cell maintenance supplemented with cytokines for differentiation, to form bone marrow organoids; and optionally d) separating the bone marrow organoids from the hydrogel for further free culture.
The use of a single compound or a combination of compounds which selectively inhibit both matrix metalloproteinases MMP-9 and MMP-12 in treating spinal cord injury (SCI), the secondary effects of SCI and related injury to neurological tissue are described, in particular the suppression of SCI-induced oedema, treatment of neuropathic pain, the prevention of functional decline following SCI and methods of administration.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.
A61K 31/7008 - Composés ayant un groupe amino lié directement à un atome de carbone du radical saccharide, p. ex. D-galactosamine, ranimustine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
Articles comprising a surface or porous substrate and having on said surface or porous substrate a coating comprising microfibrillated cellulose or nanocellulose, methods of applying a coating comprising microfibrillated cellulose or nanocellulose to a surface or porous substrate, compositions comprising microfibrillated cellulose or nanocellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating, and improving filtration efficiency and preparing an antimicrobial surface and/or antiviral surface coating.
Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
Provided are pharmaceutical compositions comprising a sulphated polysaccharide and a shear-thinning fluid gel. The sulphated polysaccharide may, by way of example, be selected from the group consisting of: a dextran sulphate having an average molecular weight of 10,000 Da or less; heparan sulphate; fucoidan; poligeenan; furcellaran; and a carrageenan. The shear-thinning fluid gel may comprise a microgel particle forming polymer, suitably selected from one or more of the following groups: gellans; alginates; carrageenans; agarose; chitosan; pectin; agarose; agar or gelatin. The compositions disclosed may be used for the prevention and/or treatment of glaucoma. These compositions may be used for the inhibition or reduction of fibrosis. The invention also relates to the medical uses of sulphated polysaccharides, and the medical uses of shear-thinning fluid gels.
An apparatus for treating TBI or TSI comprises at least two optical fibers and a light source which is operatively connected to at least one of the optical fibres. The apparatus may comprise an adapter for securing the optical fibres to the body of the subject, enabling the direct delivery of light to the brain or spinal cord. Methods and kits for treating TBI or TSI, and methods for determining the effectiveness of treatment are also provided.
Articles comprising a surface and having on said surface a coating comprising microfibrillated cellulose, methods of applying a coating comprising microfibrillated cellulose to a surface, compositions comprising microfibrillated cellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating.
A method of producing a biofilm-like microorganism-polymer complex, the method comprising the step of exposing, in an aqueous medium, cells of a microorganism to a polymer comprising groups as defined by formula (la) or formula (lb), wherein: Y comprises an imine; and R2 comprises a CI-30 group. A biofilm-like microorganism-polymer complex comprising cells of a microorganism and a polymer comprising groups as defined by formula (la) and/or formula (lb). A method for producing a chemical and/or biological product using the microorganism-polymer complex, and the chemical and/or biological products obtained therefrom. A method of dispersing the microorganism-polymer complex. Polymers of formula (la) and of formula (lb).
The invention relates to a microchannel device for preparation of sperm, the device comprising: an inlet; an extraction zone; and a channel fluidly connecting the inlet to the extraction zone; wherein the channel comprises a plurality of orienting features operable to bias a direction of sperm cell movement within the channel towards a preferred direction; and wherein the channel has a length of approximately 1 centimetre or greater. Further, the invention relates to a method of sperm preparation using the microchannel device.
A method of forming an implant for the repair of defects in bone, the method comprises the steps of:. electrospinning bioactive glass fibres;. compressing the electrospun bioactive glass fibres to form a compressed body;. heating the compressed body to bond the fibres to form a shaped body;. heat treating the shaped body to form a heat-treated shaped body. There is also disclosed an implant for use in repairing critical or sub critical bone defects.
A method of forming an implant for the repair of defects in bone, the method comprises the steps of:. electrospinning bioactive glass fibres;. compressing the electrospun bioactive glass fibres to form a compressed body;. heating the compressed body to bond the fibres to form a shaped body;. heat treating the shaped body to form a heat-treated shaped body. There is also disclosed an implant for use in repairing critical or sub critical bone defects.
The present disclosure relates to the use of ATM inhibitors, such as AZ1390 and related compounds, in the treatment of various neurological conditions, by protecting against or treating neuronal damage or neuronal degeneration, including traumatic injury, such as spinal cord injury (SCI).
Provided herein are analogues of S-adenosyl-L-methionine, methods of their preparation, and complexes and kits comprising the analogues. Said analogues find use in modifying, labelling and analysing a target molecule such as a nucleic acid.
C07H 19/167 - Radicaux purine avec un ribosyle comme radical saccharide
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12P 21/00 - Préparation de peptides ou de protéines
A method of providing a prognosis to a subject, the method comprising: i. providing a biological sample obtained from the subject; ii. determining the level of a panel of biomarkers comprising or consisting of SPATA 19, SPACA3, TSPY3, TCEA2, TSGA10, and LUZP4 in the sample; iii. comparing the level of the panel of biomarkers in the sample with a reference level of the same panel of biomarkers; iv. using the results from (iii) to provide a prognosis to the subject. More particularly, a method of providing a prognosis to a subject with cancer.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
72.
Methods and systems for measuring intraocular pressure using soundwaves
KHALIFA UNIVERSITY OF SCIENCE AND TECHNOLOGY (Ukraine)
THE UNIVERSITY OF BIRMINGHAM (Royaume‑Uni)
Inventeur(s)
Butt, Haider
Essa, Khamis
Soanes, Matt
Vahdati, Nader
Abrégé
Methods and systems for measuring the intraocular pressure of an eye in a human. The methods include directing an acoustic incident wave at the surface of the eye to generate a reflected wave, measuring the coefficient of reflection of the incident and reflected waves, and determining the intraocular pressure of the eye from the coefficient of reflection. Also disclosed are methods of diagnosing glaucoma and/or intraocular hypertension.
A61B 3/16 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la pression intraoculaire, p. ex. tonomètres
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
73.
ASSAY FOR PREDICTING RISK OF CAPECITABINE-INDUCED TOXICITY IN A SUBJECT
OXFORD UNIVERSITY INNOVATION LIMITED (Royaume‑Uni)
THE UNIVERSITY OF BIRMINGHAM (Royaume‑Uni)
Inventeur(s)
Palles, Claire
Shin Chin, Ik
Abrégé
The invention provides an assay useful in predicting risk of capecitabine-induced toxicity in a subject. The subject may be screened for the presence of at least one polymorphism of the invention. Suitable polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing capecitabine-induced toxicity; a negative result may indicate a decreased risk of developing capecitabine-induced toxicity.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A method for delaminating an electrode material of an electrode sheet from a current collector of the electrode sheet comprises positioning the electrode sheet in a sonicating bath, and at least partially within a target area of a sonotrode, wherein, in the target area, the distance between a front face of the sonotrode and the electrode sheet is less than or equal to 2 cm; and ultrasonically treating the electrode sheet, using the sonotrode, with a power density at the sonotrode front face greater than or equal to 50 W/cm2. An electrode material delaminating apparatus for performing the method is also disclosed.
H01M 10/54 - Récupération des parties utiles des accumulateurs usagés
B09B 3/30 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif impliquant un traitement mécanique
The invention relates to agents for use in preventing or reducing the interaction between S100 A8/A9 and GPIbα. Such agents are particularly for use in treating or preventing one or more inflammatory and/or thrombotic disease, such as cardiovascular diseases, chronic inflammatory diseases, infectious diseases and autoimmune diseases. An agent of the invention may be an antibody, a small molecule inhibitor, a peptide, a polypeptide, a recombinant protein, a nucleic acid, a T-cell receptor (TCR), an affibody, an aptamer, or a glycosaminoglycan.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention relates to methods for determining whether a patient suspected of being infected with Mycobacterium tuberculosis has an active or latent tuberculosis infection; to the use of certain Mycobacterium tuberculosis proteins as biomarkers for diagnosing latent tuberculosis infections; to a kit of parts comprising the Mycobacterium tuberculosis proteins; and to methods of treating latent tuberculosis infections.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A method of recycling lithium ion battery material which comprises the following steps: • comminution of lithium ion battery material to generate comminuted battery material and producing a single fraction comprising pieces of battery material; subjecting the single fraction to electrostatic separation to remove insulators and provide a conductive fraction; separating the conductive fraction using magnetic separation.
Disclosed are shear-thinning hydrogel compositions comprising 0.1 to 5 wt. % (such as 0.1 to 2.5 wt. %) of a microgel particle-forming polymer; and 0.5 to 100 mM of a monovalent and/or polyvalent metal ion salt as a cross-linking agent. The microgel particle-forming polymer is dispersed in an aqueous vehicle, and the hydrogel composition has a pH within the range of 3 to 8. The viscosity of the gel composition reduces when the gel is exposed to shear. Also disclosed are methods of making such compositions, and medical uses of such compositions.
The disclosure relates to methods and apparatus for identifying rheological properties of liquids from acoustic signals generated by liquid flow through a pipe. Example embodiments include a method of identifying a rheological property of a liquid flowing in a pipe (101), the method comprising: detecting an acoustic signal generated by the liquid flowing in the pipe using a sensor (105) attached to a rod (104) extending from a wall of the pipe (101) into the liquid; sampling the acoustic signal to provide a sampled acoustic signal; transforming the sampled acoustic signal to generate a sampled frequency spectrum; correlating the sampled frequency spectrum with a stored frequency spectrum from a database of stored frequency spectra of liquids having predetermined rheological properties; and identifying a rheological property of the liquid based on the stored frequency spectrum.
G01N 29/14 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet utilisant des techniques d'émission acoustique
G01N 29/036 - Analyse de fluides en mesurant la fréquence ou la résonance des ondes acoustiques
G01N 29/22 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet Détails
G01N 29/44 - Traitement du signal de réponse détecté
G01N 29/50 - Traitement du signal de réponse détecté en utilisant des techniques d'autocorrélation ou des techniques d'intercorrélation
An apparatus for driving atoms of an atom cloud into a targeted quantum state is provided, the apparatus comprising: an atom source for releasing a cloud of atoms to be driven into a targeted quantum state; a laser system configured to generate a laser beam to be directed onto the atom cloud in use, the laser beam having a frequency corresponding to a resonant frequency of an atomic transition for exciting the atoms into the targeted quantum state; a modulator configured to, in use, modulate the frequency of the laser beam responsive to an input signal; a waveform generator coupled to the modulator and configured to, in use, generate an input signal for the modulator, wherein the input signal is arranged to cause the modulator to modulate the laser light to generate a comb of frequencies around the resonant frequency of the atomic transition, the frequency comb including a plurality of peaks, each peak being separated by a frequency spacing, δω, that is determined based on a Rabi frequency, Ω, of the atomic transition to drive atoms of the atom cloud into a targeted quantum state.
Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and/or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 3/12 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p. ex. ophtalmoscopes
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
A method for controlling a wind turbine system connected to a power grid. The method comprises generating a wind turbine control signal based on a power control reference for controlling a power output of a wind turbine; monitoring an electrical frequency of the power grid; in response to detecting a change in the frequency in the power grid, activating a fast frequency support method comprising the steps of; adjusting the power control reference to cause an overproduction of power by the wind turbine; the overproduction of power causing a transfer of inertial kinetic energy from the wind turbine to electrical power; wherein the power control reference is determined by applying an adaptive gain function to a measurement of a difference in grid frequency from a nominal level.
F03D 7/02 - Commande des mécanismes moteurs à vent les mécanismes moteurs à vent ayant l'axe de rotation sensiblement parallèle au flux d'air pénétrant dans le rotor
F03D 9/25 - Mécanismes moteurs à vent caractérisés par l’appareil entrainé l’appareil étant un générateur électrique
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
H02J 3/00 - Circuits pour réseaux principaux ou de distribution, à courant alternatif
The present invention relates to a method for identifying whether or not it may be appropriate to administer to a subject a therapy for alleviating any potential consequences which may arise due to the subject having an atrial fibrillation (AF), the method comprising detecting, in a sample of fluid from the subject, a level of ccl21 and/or ddit4 expression and determining whether or not it may be appropriate to administer to the subject a therapy for alleviating any consequences which may arise due to the subject having AF, based upon the ccl21 and/or ddit4 expression level detected. Also provided are an anticoagulant or other AF therapy and a method of administering an anticoagulant drug or another AF therapy.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
The invention relates to a method of synthesising a modular polynucleotide, in one reaction, from two or more subunits that are each less than 100 base pairs in length.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/531 - Production de matériaux de tests immunochimiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Provided are compositions that include one or more synthetic target peptides, wherein each synthetic target peptide is about or at least 8-50 amino acids long; and has an amino acid sequence as set forth in Table 2 and/or Table 3. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro population of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically binds to a complex of an MHC class I molecule and a peptide having an amino acid sequence as set forth in Table 2 and/or Table 3, methods for treating and/or preventing cancers by administering a therapeutically effective dose of a composition that includes at least one target peptide having an amino acid sequence as set forth in Table 2 and/or Table 3.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A method of isolating or suppressing forced oscillations in a power grid by utilising a wind turbine system comprising a wind turbine for capturing wind power, a generator driven by the wind turbine, and a power converter configured to control the rotational speed of the generator for controlling a supply of active power to the power grid. The power converter is further configured to supply reactive power to the power grid independently from the supply of active power. The method comprising the steps of: obtaining measurements of a forced oscillation occurring within the power grid; controlling the converter to supply active and reactive corrective oscillating power to the power grid in response to the measured forced oscillation such that the corrective oscillating power suppresses the forced oscillations.
H02J 3/24 - Dispositions pour empêcher ou réduire les oscillations de puissance dans les réseaux
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
H02J 3/50 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs contrôlant la répartition de puissance entre les générateurs, convertisseurs ou transformateurs contrôlant la répartition de la composante déphasée
88.
BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (France)
UNIVERSITE DE PARIS (France)
UNIVERSITY OF DUNDEE (Royaume‑Uni)
TECHNICAL UNIVERSITY OF DRESDEN (Allemagne)
LUDWIG‐MAXIMILIANS‐UNIVERSITÄT MÜNCHEN (Allemagne)
UNIVERSITY OF BIRMINGHAM (Royaume‑Uni)
Inventeur(s)
Zennaro, Maria‐christina
Jefferson, Emily
Reel, Parminder Singh
Reel, Smartie
Eisenhofer, Graeme
Reincke, Martin
Beuschlein, Félix
Taylor, Angela Elizabeth
Wiebke, Arlt
Lang, Katharina
Prete, Alessandro
Abrégé
The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A single arm laser system comprising a first in-phase quadrature modulator, IQM. The first IQM is configured to receive a single frequency fibred laser beam from a frequency locked laser seed, generate a first single side-band frequency based on a carrier frequency of the single frequency fibred laser beam and suppress the carrier frequency, and output a first fibre laser beam having a single side-band suppressed carrier frequency. The single arm laser system also comprises a second IQM in line with the first IQM. The second IQM is configured to receive the first fibre laser beam from the first IQM, generate a second single side-band frequency based on the first single side-band frequency and maintain the first single side-band frequency as the carrier frequency, and output a second fibre laser beam having the first and second single side band frequencies.
G02F 1/225 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence dans une structure de guide d'ondes optique
H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
G02F 1/37 - Optique non linéaire pour la génération de l'harmonique deux
90.
PREPARATION OF COLD ATOM CLOUDS FOR MEASURING GRAVITY GRADIENT
An apparatus for generating vertically separated atom clouds. The apparatus comprises an optical system comprising an arrangement of lenses and optics. The optical system is configured to trap and cool atoms to form a cold atom cloud; select the hyperfine level of the atoms; trap atoms of the cold atom cloud in a standing wave optical lattice; and vertically split the cold atom cloud into a high cold atom cloud and a low cold atom cloud. The splitting comprises splitting the cold atom cloud into two clouds by launching atoms of the cold atom cloud in opposite directions to form a high cold atom cloud and a low cold atom cloud, and catching the low cold atom cloud up to reach the same velocity as the high cold atom cloud.
The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1 ? 54, which may be encoded by SEQ ID NOS: 55 ? 110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1 – 54, which may be encoded by SEQ ID NOS: 55 – 110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure relates to methods and products for use in detecting target RNA sequences in a sample, based on a process which nicks the DNA strand of a DNA/RNA duplex and amplifies a product thereof
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
A system for improving cognitive function is disclosed. The system comprises a non- invasive brain stimulation device (150); a human computer interface; and a computer (101) configured to control the non-invasive brain stimulation device (150) and the human computer interface. The computer (101) controls the brain stimulation device (150) and the human computer interface to assess a subject's baseline cognitive function by interaction with the subject using the human computer interface. If the subject's baseline cognitive function is impaired, the computer (101) uses the human computer interface to provide the subject with a strategy for improving performance in a cognitive function test and stimulates the subject's brain with the non-invasive brain stimulation device (150) while training the subject's cognitive function.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
95.
TOUGH, REPROCESSABLE ELASTOMERS AND METHODS OF MAKING AND USING SAME
The present disclosure describes, in part, a polymer, for example a thermoplastic polyurethane elastomer, comprising one or more subunits comprising (i) at least one dianhydrohexitole moiety (ii) at least one urethane moiety and (ill) a thiol moiety having two or more sulphur atoms. The thermoplastic polyurethane elastomers may be biodegradable and possess excellent thermoplastic properties, including outstanding toughness, resulting from its semi-crystallinity and low glass transition temperature, that surpasses many leading plastics such as nylon 6 and high-density polyethylene (HOPE) and methods of making same.
C08G 18/81 - Isocyanates ou isothiocyanates non saturés
C08F 228/02 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison au soufre ou par un hétérocycle contenant du soufre par une liaison au soufre
The present invention relates to a system and a device for use in the diagnosis of an oral disease. Methods, kits and compositions for use in the diagnosis of oral disease are also provided. More particularly, the invention relates to a system comprising a probe which is configured to collect a fluid sample from the oral cavity of a subject, and a detector which is configured to detect in the fluid sample the presence and/or concentration of an analyte which is indicative of the oral disease.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The disclosure relates to a desalination system and a method for operating the desalination system. Example embodiments include a desalination system (100) comprising a partitioned container (101), a membrane container (104) housing a cross- flow semipermeable membrane (105), a feed pump (108) for supplying saline water, a recirculation pump (109), a main valve (110), a bypass valve (111) and a purge valve (112). The system (100) operates in a first pressurisation stage where saline water is provided by the feed pump (108) while the bypass valve (111) is open, followed by a second pressurisation stage where an upstream compartment (114) of the container (101) is filled and a recharge stage where the main valve (110) is closed and concentrated saline water is purged via the purge valve (112). An inlet valve (116) may be provided, which is closed in the first pressurisation stage and open in the second pressurisation stage and recharge stage.
The invention relates to a genetic probe, wherein the genetic probe comprises: an oligonucleotide, or an oligonucleotide analogue, with a Raman-active moiety incorporated therein, wherein the Raman-active moiety is incorporated into a base of the oligonucleotide or oligonucleotide thereof; and associated methods, uses, kits and compositions for determining a single point variant nucleotide in a target nucleic acid.
The present invention relates to a drug delivery system and methods of using the delivery system, particularly a delivery system for transporting pharmaceutically active agents across, for example, the skin, the surface of the eye or mucosal membranes. The drug delivery system comprises a pharmaceutically effective moiety and a polyamine or amine moiety, wherein the polyamine or amine moiety does not comprise two or more contiguous basic amino acid residues. The drug delivery system may be provided for use as a medicament, or for use in the treatment of a disease or condition selected from eye disease, burns, infection, and trauma. The invention also provides a method comprising administering a pharmaceutically effective amount of the drug delivery system of the invention to a patient in need thereof.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The present disclosure relates to the treatment of eye conditions, by inhibiting Chk2 kinase. Particular ocular conditions may be associated with neuronal damage/dysfunction in the eye, or neurons in communication with the eye, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption in blood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.
A61K 31/4422 - 1,4-Dihydropyridines, p. ex. nifédipine, nicardipine
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 27/00 - Médicaments pour traiter les troubles des sens
